Introduction
Thoracic esophageal squamous cell carcinoma (ESCC) consists of >90% of the esophageal cancer cases in East Asia, and tumors located in the upper and middle thoracic esophagus (Mt) are most commonly observed. Surgery is still a preferred therapeutic
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Zhou et al strategy for patients with thoracic ESCC. However, the recurrence rate of ESCC is as high as 50% after radical surgery during the follow-up period, 1 and locoregional recurrence (especially single-station lymph node recurrence) is the major cause of treatment failure, 2, 3 which correlated with an unfavorable prognosis.
At present, chemoradiotherapy (CRT) is the main treatment method for the patients with secondary lymph node metastasis (LNM) after esophagectomy; however, the therapeutic effect has not been obviously improved, and this phenomenon may be related to the gross tumor volume (GTV) of metastatic lymph nodes (V LN ) and maximum diameter of metastatic lymph nodes (D LN ). It is generally recognized that the high tumor burden is correlated with poor sensitivity of CRT, and the long-term prognosis is inferior. Chen et al 4 reported that GTV defined on radiotherapy (RT) planning scans may serve as a good prognostic factor for ESCC patients treated with radical RT; however, the prognostic value of the patients with postoperative nodal recurrences who underwent RT or CRT remains unclear.
Recently, some trials reported a close relationship between systemic hematological markers and prognosis in human malignancies, [5] [6] [7] [8] [9] and the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been studied in various malignancies. [10] [11] [12] [13] [14] [15] These markers, which can be measured easily and inexpensively, are widely used in clinical practice and may contribute to predict an unfavorable prognosis in patients with esophageal carcinoma. 10, 16, 17 This correlation has been well documented in other types of human malignancies, but the combination of tumor burden markers, which are represented by GTV and maximum diameter, and hematological markers has rarely been studied in patients with LNM after resection of ESCC. Therefore, the purpose of this study was to clarify whether pretreatment tumor burden-related index and inflammatory markers, including V LN, D LN , NLR, and PLR, were useful for assessing the therapeutic effects and prognosis with LNM receiving CRT or radiation (RT) alone after resection of ESCC.
Patients and methods Patients
Between January 2011 and December 2014, a total of 119 esophageal carcinoma patients with secondary LNM after resection of ESCC at the Department of Thoracic Surgery, the Affiliated Taixing People's Hospital of Yangzhou University were recruited in this retrospective study. The inclusion criteria were as follows: 1) secondary LNM after curative esophagectomy; 2) the diagnosis of LNM was performed by pathologic conformation or short axis of ≥10 mm in mediastinum and cervix or short axis of ≥5 mm in tracheoesophageal groove with enhanced computed tomography (CT) imaging; 3) normal liver and renal function, without severe dysfunction of important organs, and overall performance status of 0 or 1; 4) complete record of pretreatment hematological variables; 5) no presence of distant metastasis; 6) the patients with complete follow-up time ≥1 year; 7) no presence of infection or inflammatory conditions, such as rheumatologic conditions, connective tissue disorders, or heart diseases. Finally, 119 patients were enrolled and analyzed in this study. Clinicopathological features were obtained from the patients' records. This research was approved by the ethics committee of the Affiliated Taixing People   ' s Hospital of Yangzhou University. Informed consent was obtained from all individual participants included in this study.
Treatment modalities
All patients were treated with three-dimensional conformal RT (3-DCRT). Definitive RT alone (n=32) or in combination with chemotherapy (n=87) was intended to be administered. All treatments were planned based on CT simulation planning system with 4 mm thickness scan slice throughout the entire neck and thorax. A total dose of up to 60.0-64. The target volumes were defined as follows: 1) GTV: metastatic lymph node; 2) clinical target volume (CTV): GTV +2 cm margins in the metastatic lymph node long axis, superiorly and inferiorly to encompass potential invasions; and 3) planning target volume (PTV): CTV +0.5 cm margin.
Assessment of therapeutic effect
Clinical responses were assessed by CT scan 1 month after RT with or without two cycles of chemotherapy. Tumor response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). 18 Accordingly, tumor response was divided into four groups as follows: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Patients demonstrating CR or PR after treatment were defined as responders, whereas those exhibiting SD or PD were classified as non-responders.
Data collection and follow-up
Images were retrieved from the patients' database, and the GTV and maximum diameter of metastatic lymph nodes (V LN and D LN ) were calculated using the Monaco 5.1 system for each patient. 
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The following pretreatment hematological parameters were collected within 1 week prior to the initial treatment: neutrophil count, lymphocyte count, monocyte count, and platelet count. The NLR and PLR were calculated by division of the absolute values of the corresponding hematological parameters.
After the completion of treatment, all patients were asked to return to the hospital for examination every 3 months for the first year, every 6 months for the next 2 years, and then annually. The duration of follow-up was calculated from the day of treatment to the day of death or July 2017.
Statistical analysis
V LN , D LN , NLR, and PLR were divided into high/low group by the corresponding median value. Univariate logistic analysis was performed to determine which variables were associated with response to therapy. Variables generating P-values ≤ 0.05 by univariate logistic analysis were subjected to multivariate logistic regression analysis.
The overall survival (OS) curves based on pretreatment V LN , D LN , NLR, and LMR were plotted using the KaplanMeier method, and differences were assessed by the log-rank test. Univariate and multivariate analyses of Cox regression proportional hazard model were used to evaluate the influence of each variable on OS with the enter method. Hazard ratio (HR) with 95% confidence interval (CI) was used to quantify the strength of the association between predictors and survival. ROC curves were also plotted to verify the accuracy of V LN , D LN , NLR, and PLR for therapeutic effect and OS prediction. A two-tailed P-value ≤ 0.05 was considered statistically significant. Statistical analyses were performed using the Statistical Package for Social Sciences version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients and clinicopathological features
A total of 87 male (73.1%) and 32 female (26.9%) patients were investigated. The median age was 63 years (range: 46-78). Primary tumors were located in the upper thoracic esophagus (Ut) in six patients (5.0%), in the Mt in 78 patients (65.5%), and in the lower thoracic esophagus (Lt) in 35 patients (29.5%). Single RT was administered to 32 patients; concurrent CRT was delivered to 87 patients. With a median follow-up time of 18 months (range: 4-36 months), 94 patients (79%) were dead at the end of follow-up time. The clinical and pathological characteristics of 119 patients are shown in Table 1 .
Correlation between therapeutic efficacy and V LN , D LN , NLR, and PLR
A total of 119 patients with LNM after resection of esophageal carcinoma were grouped according to the median values of NLR, PLR, and the size of LNM, including V LN For all patients, the median OS time was 16 months. The OS rates at the 1-, 2-, and 3-year period were 69.7%, 28.6%, and 21.1%, respectively. As shown in Figure 1 , in the NLR < 3.33 group, the 1-, 2-, and 3-year OS rates were 79.7%, 45.5%, and 40.6%, respectively, while in the NLR ≥ 3.33 group, the OS rates were 60.4%, 11.8%, and 2.7%, respectively ( Figure 1A ; c 2 =27.298, P=0.000). In the PLR < 154.24 group, the 1-, 2-, and 3-year OS rates were 80.0%, 40.0%, and 36.7%, respectively, and in the PLR ≥ 154.24 group, the OS rates were 59.3%, 16.9%, and 5.1%, respectively ( Figure 1B; Figure 1C ; c 2 =48.823, P=0.000). In addition, in the D LN < 4.61 cm group, the 1-, 2-, and 3-year OS rates were 84.7%, 52.5%, and 42.4%, respectively, while in the D LN ≥ 4.61 cm group, the OS rates were 55.0%, 6.9%, and 1.6%, respectively ( Figure 1D ; c 2 =40.724, P=0.000). Figure 1 shows the OS curves based on pretreatment NLR, PLR, V LN , and D LN . Our results indicated that NLR, PLR, V LN , D LN , and treatment methods were significantly associated with OS using the univariate analysis. Furthermore, multivariate Cox proportional hazard regression model analysis for OS was performed to identify the prognostic factors for enrolled patients treated with RT or CRT. The results showed that NLR, V LN , D LN , and therapeutic method were considered independent prognostic factors for OS, whereas PLR did not indicate a statistical difference associated with OS (Table 3) . (Figure 2 ). As shown in Figure 2A, Figure 2B ).
Correlations among the NLR and PLR, V LN , and D LN
As shown in Figure 1 , univariate analysis showed that a high NLR and PLR and a high V LN and D LN were all individually associated with an unfavorable survival outcome.
Furthermore, the correlations between PLR and NLR and between V LN and D LN were examined using Pearson correlation analysis (Figure 3) . The results showed that there were moderate correlations between PLR and NLR and between V LN and D LN (correlation coefficient R 2 =0.493 and 0.572, respectively).
Discussion
There are several clinical data supporting that the survival of cancer patient is determined not only by tumor itself but also by host-related factors, such as the systemic inflammatory Note: V LN , the gross tumor volume of metastatic lymph nodes; D LN , the maximum diameter of metastatic lymph nodes. Abbreviations: CI, confidence interval; ESCC, esophageal squamous cell carcinoma; LNM, lymph node metastasis; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-tolymphocyte ratio. 
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Influential factors on radiotherapy efficacy and prognosis in LNM status. In this clinical study, we investigated the significance for the tumor treatment response and survival prognosis of inflammatory markers and tumor burden-related index in patients with secondary LNM after resection of ESCC. This study indicated that NLR (P=0.019), treatment strategies (P=0.032), and V LN (P=0.034) were independent risk factors for tumor treatment efficacy. While the NLR, V LN , and D LN were considered independent prognostic factors for OS. To our knowledge, this is the first report to demonstrate the clinical significance of NLR, PLR, V LN , and D LN in patients with LNM receiving CRT or RT after esophagectomy. At present, surgery is the most important treatment strategy for patients with non-metastatic thoracic ESCC. However, the prognostic outcome is unsatisfactory, and the recurrence rate of ESCC is high after radical surgery. Liu et al 1 demonstrated that ~50% of patients with ESCC developed treatment failure during the follow-up period. Single-station LNM was the most common type of failure and the location of metastasis in the bilateral supraclavicular areas as well as the superior mediastinum was more frequent than in other regions. In the clinical practice, the OS rate of patients with locoregional recurrence was worse, and one of the reasons may consist of tumor volume affecting prognostic outcomes. One previous study demonstrated that larger GTV did predict a poorer prognosis in ESCC patients treated with radical radiochemotherapy. 4 A large tumor burden means more hypoxic cells, which is resistant to treatment, so the prognosis is worse. The negative impact of tumor hypoxia on survival is related to radiobiological mechanisms caused by hypoxia, which may include 1) the reduced oxygen enhancement effect, 2) increased radioresistance due to expression of genes for cell cycle delay and stress proteins, and/or 3) accelerated tumor progression to more radioresistant and metastatic variants by increased genetic heterogeneity. 19 In the present study, we determined that the GTV and maximum diameter of metastatic lymph nodes (V LN and D LN ) are useful for assessing the therapeutic effects and prognosis in ESCC patients with LNM after resection. The results found that patients who suffered the large tumor burden (V LN ≥ 48.12 cm 3 and D LN ≥ 4.61 cm) had significantly worse therapeutic efficacy and OS than those who suffered small tumor burden (V LN < 48.12 cm 3 and D LN < 4.61 cm).
In the case of hematological markers, a high NLR was significantly associated with poor response to treatment and unfavorable OS in patients with LNM after resection of ESCC. Since the pathologist Rudolf Virchow first discovered leukocytes in malignant tissue specimens ~150 years ago, 20 the prognostic values of pretreatment hematological markers have been highlighted. Currently, compelling evidence suggested that there were statistically significant differences in the therapeutic response and survival rates grouped by blood inflammatory markers for several types of malignancies. [10] [11] [12] [13] [14] [15] 21, 22 Multiple studies have demonstrated that hyperfibrinogenemia and elevated NLR or the combination of NLR with PLR were the predictors of poor therapeutic Tumor cells can produce granulocyte colony-stimulating factor, tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6, which can influence leukocyte and neutrophil counts in the bloodstream. 24 Some research also showed that platelets could enhance hematogenous metastasis by stabilizing tumor cell arrest in the vasculature, activating tumor cell proliferation, boosting tumor cell extravasation, and enhancing tumor cell interaction with the extracellular matrix. 25 In contrast, lymphocytopenia can also stimulate the release of suppressive immunological mediators, such as transforming growth factor-β (TGF-β) and IL-10, resulting in immunosuppression and consequently weakening of the lymphocyte functions. 26 Our univariate analysis suggested that the pretreatment NLR and PLR were independent risk factors for therapeutic responsiveness and OS in patients with LNM after esophagectomy. Furthermore, the multivariate analysis showed that only NLR < 3.33 had significantly better therapeutic efficacy (HR=2.697, 95% CI: 1.201-7.429, P=0.019) and OS (HR=2.000, 95% CI: 1.127-3.548, P=0.018) than those who had NLR ≥ 3.33
This study has several potential limitations. First, concerning diagnostic criteria of LNM, the selection of enrolled patients mainly depended on positive CT scans instead of pathological biopsy during the observation period, which might have led to an inherent bias. Second, not all hematological markers of inflammation were used in this analysis, because some biomarkers were not routinely examined, such as C-reactive protein 27, 28 and fibrinogen. 21 Third, it was a single-institution, retrospective study. Finally, 119 patients were enrolled in this study, and the sample size is small and may be insufficient to strengthen our results. Given these limitations, future larger randomized trials are needed to clarify these results.
Conclusion
In summary, this study demonstrated that NLR and V LN were promising as predictive markers for therapeutic effects, and NLR combined with V LN and D LN might be useful biomarkers in predicting outcomes in patients with LNM receiving CRT or single RT after esophagectomy. However, considering the retrospective nature of this study, large-scale prospective trials are still warranted to verify these results.
